EMBL Australia

Research led by EMBL Australia group leader Dr Harald Janovjak has revealed the potential of optogenetics - a relatively new and rapidly evolving technology - to treat Parkinson's disease.

News this quarter:

• A tribute to Scientia Professor Katharina Gaus FAHMS
• Reversing severe muscle wasting in disease, ageing & trauma
• Hint as to how SARS-CoV-2 might subvert immune defences
• Enabling the early and accurate diagnosis of Parkinson’s disease
• More than $4.8m awarded to EMBL Australia researchers in NHMRC Ideas Grants
• This protein empowers cancer cells – targeting it could kickstart new therapies
• Professor Ian Smith to chair the EMBL Australia Council
• Innovative research takes us one step closer to developing an effective malaria vaccine
• Did you know you can access EMBL’s cutting-edge scientific services?
• Get to know: Dr Vaishnavi Ananthanarayanan

 

And more:

• Job opportunities
• Upcoming events
• Recent publications

Dr Vaishnavi Ananthanarayanan recently joined EMBL Australia as a Group Leader, based at UNSW's Single Molecule Science.

Farewell to world-leading immunologist and molecular microscopist Scientia Professor Katharina Gaus - a visionary scientist, inspirational mentor, and much-loved friend, colleague and collaborator.

Despite the challenges and disruptions imposed by the global COVID-19 pandemic, the EMBL Australia Partner Laboratory Network continued to produce fantastic science, attract highly competitive research grants and grow in size. Many of our researchers contributed scientifically to the international battle against coronavirus and continued to build up Australia's research infrastructure capabilities across the various PLN host institutions.

An exciting discovery by Monash University scientists - including members of EMBL Australia's leadership team, Professor Peter Currie and Associate Professor Mikaël Martino - may lead to faster recovery from muscle injury and wasting diseases.

We are excited to welcome the newest member of the EMBL Australia Council, Professor Ian Smith, who replaced the outgoing Professor Brandon Wainwright AM as chairperson, in November 2020.

A new detection method co-developed by EMBL Australia group leader Dr Yann Gambin could enable the early and accurate detection of Parkinson’s disease, vastly improving patient outcomes.

An international study co-led by EMBL Australia group leader Dr Yann Gambin has revealed a potential mechanism the SARS-CoV-2 virus may use to try to temper the host’s innate immune defence.

A clinical human trial of malaria infection led by EMBL Australia group leader Dr Michelle Boyle has linked the activation of specific immune cells to the induction of protective antibodies against malaria - an important step towards the development of an effective vaccine.